OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Mice treated with a metalloproteinase that cleaves an IGF-binding protein and decreases IGF-I bioavailability have a 38% longer lifespan and a lower tumor incidence
There are several uses and benefits of the IGF1 LR3, including the boost in metabolic rate, burning fat reserves, and increase in muscle building capacity
tradekorea seller basic 1 time 1 additional time provided (if attendance is successful 2 times a week) Benefit 1
Rotating between sites prevents localized tissue irritation from repeated injection
Associated toxicity includes potential headaches and bleeding problems